Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
The Chief Financial Officer of a biopharmaceutical issuer filed a Form 4 showing open-market sales of common stock on February 4–5, 2026. On February 4, the officer sold 1,500 shares at a weighted average price of $104.7434, 1,000 shares at $106.604, and 747 shares at $107.6654. On February 5, the officer sold an additional 3,381 shares at $106.063.
After these transactions, the officer directly beneficially owned 125,537 shares of common stock. The filing notes that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, and that each reported price is a weighted average for multiple trades within the stated price ranges.
A person filing on behalf of RYTM has submitted a Form 144 notice covering a planned sale of 18,406 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 5, 2026. The shares have an indicated aggregate market value of $1,987,295.82, compared with 66,736,056 shares of common stock outstanding. These shares were acquired as restricted stock units from the issuer on February 10, 2025. The form also notes a prior Rule 10b5-1 sale for Hunter Smith of 3,247 common shares on February 4, 2026, generating gross proceeds of $344,145.31.
A shareholder of RYTM filed a Form 144 notice to sell up to 3,247 shares of common stock through Morgan Stanley Smith Barney LLC on or about February 4, 2026 on NASDAQ. The filing shows an aggregate market value of $351,617.63 for these shares.
The shares to be sold were acquired from the issuer as restricted stock units on February 3, 2025, in the same amount of 3,247 shares. The table also lists 66,736,056 shares outstanding for this class of common stock.
EVP, Head of International Yann Mazabraud reported an equity award transaction involving restricted stock units and common stock of Pharmaceuticals, Inc. (ticker RYTM). On February 1, 2026, 5,500 restricted stock units were converted into 5,500 shares of common stock at $0 per share under transaction code M.
Following this transaction, Mazabraud directly beneficially owned 43,155 shares of common stock and 11,000 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 25% increments on February 16, 2025, and February 1 of 2026, 2027, and 2028.
The Chief Financial Officer, Hunter C. Smith, reported equity compensation activity involving company stock on February 1, 2026. He converted 26,000 shares of common stock from restricted stock units, bringing his directly held common shares to 132,165 after the reported transactions.
To cover withholding taxes upon vesting, 10,750 common shares were withheld at a price of $108.99 per share, rather than being sold in the open market. The underlying restricted stock units convert into one share of common stock each and vest in four equal annual installments, with various grants vesting through February 2029. The restricted stock units have no expiration date.
Pharmaceuticals, Inc. Chief Technical Officer Joseph Shulman reported the vesting of 16,968 shares of common stock on February 1, 2026 from multiple restricted stock unit (RSU) awards. Each RSU converts into one share of common stock.
To satisfy withholding taxes on this vesting, 6,507 shares were withheld at $108.99 per share. After these transactions, Shulman directly beneficially owned 18,970 shares of common stock and continues to hold additional RSUs that vest in stages through 2029.
Pharmaceuticals, Inc. President and CEO David P. Meeker reported equity award activity on February 1, 2026. A total of 68,713 shares of common stock were acquired through the vesting and settlement (code M) of previously granted restricted stock units, increasing his directly held common shares to 270,538 before tax withholding.
On the same date, 31,522 shares of common stock were withheld at $108.99 per share (code F) to cover withholding taxes related to the vesting, leaving Meeker with 239,016 directly owned common shares. Multiple restricted stock unit awards converted into common stock, and the filing notes that each unit represents the right to receive one share of common stock and that these units vest in four equal annual installments with no expiration date.
Pharmaceuticals, Inc.’s EVP and Head of North America, Jennifer Kayden Lee, reported routine equity activity on February 1, 2026. Restricted stock units converted into 22,612 shares of common stock, increasing her directly held stake before tax withholding.
To cover withholding taxes on the vesting, 9,237 common shares were withheld at $108.99 per share, leaving her with 19,233 shares of common stock held directly after the transactions. Several restricted stock unit awards continue to vest annually through dates ranging from February 1, 2027 to February 1, 2029, with remaining balances including 4,512, 11,000, and 27,487 restricted stock units.
Rhythm Pharmaceuticals, Inc. Corporate Controller & CAO Christopher Paul German reported routine equity compensation activity on February 1, 2026. A total of 3,613 shares of common stock were acquired upon the vesting and settlement of restricted stock units at an exercise price of $0.
The company then withheld 1,138 shares at a price of $108.99 to cover tax obligations tied to this vesting. After these transactions, German directly owned 3,433 shares of common stock, including 36 shares previously purchased through the employee stock purchase plan, plus ongoing holdings of restricted stock units that vest in annual 25% installments through 2029.
Pharmaceuticals, Inc.’s Chief Scientific Officer Alastair Garfield reported a routine equity compensation event. On February 1, 2026, 6,663 restricted stock units (RSUs) were converted into 6,663 shares of common stock at an exercise price of $0. Of these, 2,026 shares were withheld at $108.99 per share to cover tax withholding, leaving Garfield with 7,763 shares of common stock directly owned. He also directly holds 19,987 RSUs, which vest in four equal 25% installments on February 1 of 2026, 2027, 2028, and 2029, with no expiration date.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
